ASH 2022 showcased incredible scienceand research developments in the cell and gene therapy field.
Of the approximately 6,439 abstracts submitted, over 50% were focused on CGT.
Here are our key highlights….
New Data
Lots of study results presented at ASH focused on new data for alternative chemotherapy, immunotherapy and combinational therapeutic options.
New data from companies like Kite, Janssen, Novartis and Bluebird, and academic groups like UPenn’s Abramson Cancer Center, showcased the clinical investments being made in CGT.
Topics for discussion
The main focus of the conference was on improving clinical outcomes, recognizing & managing cell therapy toxicities, and exploring the application of CGTs to new indications.
Approvable, accessible and affordable
Given the investment, research and positive results of CGTs – and the continued challenges the industry is facing around patient access for currently approved therapies – it is important that, as an industry, we have collaborative discussions about manufacturing.
We need to ensure that advanced therapies are not just approvable, but are accessible and affordable.
Approvable, accessible and affordable
Given the investment, research and positive results of CGTs – and the continued challenges the industry is facing around patient access for currently approved therapies – it is important that, as an industry, we have collaborative discussions about manufacturing.
We need to ensure that advanced therapies are not just approvable, but are accessible and affordable.
The time for action is now…
“There’s a mounting global cancer crisis. By 2040, new cancer diagnoses are expected to double…estimates are that there’ll be over 18 million deaths from cancer worldwide.”
Molly Tokaz MD, Fred Hutchinson Cancer Center
